17 Papers
Lili Lu is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Oxidative stress & SOD2. The author has an hindex of 17, co-authored 17 publications.
Chat about Author
Papers
Cloning of the gamma-aminobutyric acid (GABA) rho 1 cDNA: a GABA receptor subunit highly expressed in the retina.
Garry R. Cutting,Lili Lu,Bruce F. O'Hara,Laura Kasch,C Montrose-Rafizadeh,D M Donovan,S Shimada,Stylianos E. Antonarakis,William B. Guggino,George R. Uhl +9 more
TL;DR: Features are consistent with the identification of a GABA subunit, GABA rho 1, with prominent retinal expression that increases the diversity and tissue specificity of this ligand-gated ion-channel receptor family.
447
Antioxidants reduce cone cell death in a model of retinitis pigmentosa.
TL;DR: The hypothesis that gradual cone cell death after rod cell death in RP is due to oxidative damage, and that antioxidant therapy may provide benefit, is supported.
429
Is There Excess Oxidative Stress and Damage in Eyes of Patients with Retinitis Pigmentosa
Peter A. Campochiaro,Rupert W. Strauss,Lili Lu,Gulnar Hafiz,Yulia Wolfson,Syed Mahmood Shah,Raafay Sophie,Tahreem A. Mir,Hendrik P. N. Scholl +8 more
TL;DR: Patients with RP have ocular oxidative stress and damage in the absence of manifestations of systemic oxidativestress and/or damage indicating that demonstrations of oxidative damage-induced cone cell death in animal models of RP may translate to human RP.
N-Acetylcysteine promotes long-term survival of cones in a model of retinitis pigmentosa.
Sun Young Lee,Shinichi Usui,Abu bakr Zafar,Brian C. Oveson,Young Joon Jo,Lili Lu,Solmaz Masoudi,Peter A. Campochiaro +7 more
TL;DR: Oral administered N‐acetylcysteine (NAC) reduced cone cell death and preserved cone function by reducing oxidative damage in two models of RP, rd1+/+ and rd10+/+ mice and it is reasonable to consider clinical trials to evaluate the effects of prolonged treatment with NAC.
102
Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial.
Peter A. Campochiaro,Mustafa Iftikhar,Gulnar Hafiz,Anam Akhlaq,Grace Tsai,Dagmar Wehling,Lili Lu,G. Michael Wall,Mandeep S. Singh,Xiangrong Kong +9 more
TL;DR: A randomized, placebo-controlled trial is needed to determine if oral NAC can provide long term stabilization and/or improvement in visual function in patients with moderately advanced RP and may improve suboptimally functioning macular cones.